Table 5 Diagnostic performance of the composite panel of three miRNAs in a testing cohort of patients with malignant SPNs and patients with benign SPNs
| Â | Sensitivity | Specificity |
|---|---|---|
All cases | 76.32% | 85.00% |
Different histological types * | Â | Â |
   AC | 75.00% | 85.00% |
   SCC | 77.78% | 85.00% |
Cases with different stages * | Â | Â |
   I | 75.00% | 85.00% |
   II | 80.00% | 85.00% |
   III-IV | 72.73% | 85.00% |